JP2022538117A5 - - Google Patents
Info
- Publication number
- JP2022538117A5 JP2022538117A5 JP2021576582A JP2021576582A JP2022538117A5 JP 2022538117 A5 JP2022538117 A5 JP 2022538117A5 JP 2021576582 A JP2021576582 A JP 2021576582A JP 2021576582 A JP2021576582 A JP 2021576582A JP 2022538117 A5 JP2022538117 A5 JP 2022538117A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025107324A JP2025175994A (ja) | 2019-06-26 | 2025-06-25 | がんを処置するための抗ｃｄ３３抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867032P | 2019-06-26 | 2019-06-26 | |
| US62/867,032 | 2019-06-26 | ||
| PCT/US2020/039687 WO2020264211A1 (en) | 2019-06-26 | 2020-06-25 | Anti-cd33 antibodies for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107324A Division JP2025175994A (ja) | 2019-06-26 | 2025-06-25 | がんを処置するための抗ｃｄ３３抗体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022538117A JP2022538117A (ja) | 2022-08-31 |
| JP2022538117A5 true JP2022538117A5 (https=) | 2023-07-03 |
| JPWO2020264211A5 JPWO2020264211A5 (https=) | 2023-07-03 |
| JP7788859B2 JP7788859B2 (ja) | 2025-12-19 |
Family
ID=74059823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576582A Active JP7788859B2 (ja) | 2019-06-26 | 2020-06-25 | がんを処置するための抗ｃｄ３３抗体 |
| JP2025107324A Pending JP2025175994A (ja) | 2019-06-26 | 2025-06-25 | がんを処置するための抗ｃｄ３３抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107324A Pending JP2025175994A (ja) | 2019-06-26 | 2025-06-25 | がんを処置するための抗ｃｄ３３抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220251192A1 (https=) |
| EP (1) | EP3990022A4 (https=) |
| JP (2) | JP7788859B2 (https=) |
| CN (1) | CN114401744B (https=) |
| CA (1) | CA3149683A1 (https=) |
| WO (1) | WO2020264211A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| CN114401744B (zh) * | 2019-06-26 | 2024-11-05 | 纪念斯隆凯特琳癌症中心 | 用于治疗癌症的抗cd33抗体 |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| WO2021242848A1 (en) * | 2020-05-27 | 2021-12-02 | Memorial Sloan Kettering Cancer Center | Anti-gd2 sada conjugates and uses thereof |
| EP4608871A1 (en) * | 2022-10-26 | 2025-09-03 | Memorial Sloan-Kettering Cancer Center | Cd33 antibody compositions for treating alzheimer's disease |
| CN116375874B (zh) * | 2023-04-14 | 2023-12-26 | 上海精翰生物科技有限公司 | 一种cd33抗体及其应用 |
| CN118580357A (zh) * | 2024-08-07 | 2024-09-03 | 上海交通大学医学院附属仁济医院 | 一种cd33特异性单克隆抗体及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6599505B1 (en) * | 1992-04-10 | 2003-07-29 | Research Development Foundation | Immunotoxins directed against CD33 related surface antigens |
| BR0316101A (pt) * | 2002-11-07 | 2005-09-27 | Immunogen Inc | Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos |
| DE102009045006A1 (de) * | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| CN106456762A (zh) * | 2014-05-20 | 2017-02-22 | 伊缪诺金公司 | 用于表征和治疗急性髓样白血病的方法 |
| SG10201913765YA (en) * | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| US10519248B2 (en) * | 2014-07-25 | 2019-12-31 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| CN108290939B (zh) * | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
| JOP20170091B1 (ar) * | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
| US20190233534A1 (en) * | 2016-07-14 | 2019-08-01 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| AU2017355402A1 (en) * | 2016-11-02 | 2019-05-30 | Health Research, Inc. | Combination treatment with antibody-drug conjugates and PARP inhibitors |
| KR20190140943A (ko) * | 2017-04-24 | 2019-12-20 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd33 항체 제제 |
| US11583588B2 (en) * | 2017-05-05 | 2023-02-21 | Memorial Sloan Kettering Cancer Center | Modular self assembly disassembly (SADA) technologies |
| JP2020519640A (ja) * | 2017-05-17 | 2020-07-02 | イミュノジェン， インコーポレイテッド | 抗ｃｄ３３イムノコンジュゲート投与計画 |
| US11565005B2 (en) * | 2017-07-06 | 2023-01-31 | Memorial Sloan Kettering Cancer Center | Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy |
| CN111372610B (zh) * | 2017-09-22 | 2023-05-30 | 伊缪诺金公司 | 防止免疫结合物中的甲硫氨酸氧化的方法 |
| US20190153096A1 (en) * | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
| CN114401744B (zh) * | 2019-06-26 | 2024-11-05 | 纪念斯隆凯特琳癌症中心 | 用于治疗癌症的抗cd33抗体 |
-
2020
- 2020-06-25 CN CN202080059807.6A patent/CN114401744B/zh active Active
- 2020-06-25 WO PCT/US2020/039687 patent/WO2020264211A1/en not_active Ceased
- 2020-06-25 CA CA3149683A patent/CA3149683A1/en active Pending
- 2020-06-25 JP JP2021576582A patent/JP7788859B2/ja active Active
- 2020-06-25 EP EP20831640.6A patent/EP3990022A4/en active Pending
- 2020-06-25 US US17/621,815 patent/US20220251192A1/en active Pending
-
2025
- 2025-06-25 JP JP2025107324A patent/JP2025175994A/ja active Pending